News
Article
Author(s):
Paul Offit removed from FDA vaccine panel as RFK Jr. reshapes US immunization policy, raising concerns for bio/pharma and regulation.
Silver Spring, MD, USA - June 25, 2022: Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services | Image Credit: © Tada Images - stock.adobe.com.
Major shifts in federal vaccine policy under Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. are reshaping the advisory landscape that underpins US vaccine approvals and immunization strategy (1). These developments could signal a more unpredictable regulatory environment with direct implications for vaccine development, manufacturing, and commercialization.
Paul Offit, pediatrician and co-inventor of the rotavirus vaccine, was recently removed from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC)—a panel central to evaluating vaccine safety and efficacy data for approval (1). Although Offit had previously agreed to a two-year term extension at the agency’s request, his position was abruptly terminated. HHS stated that approximately a dozen advisory members across eight FDA panels were removed after their service terms expired, but no clarity was provided on renewals.
Offit’s removal follows a series of high-profile exits driven by policy changes:
For vaccine developers, these shifts raise several critical issues:
Kennedy is set to appear before the Senate Finance Committee this week, where lawmakers are expected to question his vaccine policy decisions (1). The outcome may provide early signals on whether Congress could intervene or push back against the erosion of traditional scientific advisory mechanisms.
As the regulatory climate continues to shift, bio/pharma companies should prepare for greater political volatility in vaccine policy, with implications for development pipelines, regulatory strategy, and long-term commercial planning.
References
1. Karlin-Smith, S; Gingery, D. Offit’s VRBPAC Departure Raises Questions About Another HHS Panel Revamp. Insights.Citeline.com.Pink-Sheet. September 2, 2025.
2. Edwards, E; Lovelace Jr, B. CDC Director Susan Monarez fired by Trump administration after refusing to resign, citing 'reckless directives'. NBCNews.com. August 27, 2025.
3. Barna, M. CDC leaders fight back in wake of attack on agency, public health. APHA.org. August 29, 2025.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.